Vinod Bambure
Research Subjects
Vinod Bambure has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Caplanusi
12GlaxoSmithKline Vaccines, Wavre, Belgium
1 shared publication - Angkool Kerdpanich
Infectious Diseases Unit, Department of Pediatrics, Phramongkutklao Hospital, Bangkok, Thailand
1 shared publication - Anuradha Madan
GSK, 1250 South Collegeville Road, Collegeville, PA 19426, USA
1 shared publication - David W. Vaughn
A GlaxoSmithKline Vaccines ; Rixensart , Belgium
1 shared publication - Emmanuel Hanon
GlaxoSmithKline Vaccines; Rixensart, Belgium
1 shared publication François Roman
GlaxoSmithKline Vaccines; Wavre, Belgium
1 shared publication
Latest Publications
- Open Access
- 16 September 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 435
Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials
Pandemic influenza vaccine manufacturing capacity and distribution agility is enhanced through the availability of equivalent antigen-sparing vaccines. We evaluated equivalence in terms of immunogenicity between GlaxoSmithKline Vaccines’ A/California/7/2009 (H1N1)v-like-AS03 vaccines manufactured in Dresden (D-Pan), and Quebec (Q-Pan).
- 16 September 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 435
Open AccessExtended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials
Pandemic influenza vaccine manufacturing capacity and distribution agility is enhanced through the availability of equivalent antigen-sparing vaccines. We evaluated equivalence in terms of immunogenicity between GlaxoSmithKline Vaccines’ A/California/7/2009 (H1N1)v-like-AS03 vaccines manufactured in Dresden (D-Pan), and Quebec (Q-Pan).
- 9 April 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 9 (7) , 1512-1522
Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine
This manuscript presents data on the persistence of Hemagglutination Inhibition (HI) immune response against the A/California/7/2009 strain, six and 12 mo after adults received one dose (n = 138) or two doses (n = 102; 21 d apart) of a 3.75 µg Hemagglutinin antigen AS03-adjuvanted H1N1 2009 vaccine (NCT00968526). Two hundred forty subjects (18−60 y: 120; > 60 y: 120) were vaccinated. Immunogenicity end points were based on the European licensure criteria for pandemic influenza vaccines. Exploratory analyses assessed the cell-mediated immune response (CMI) up to Month 12 and the influence of previous influenza vaccination on persistence of immune response. At Month 6, the CHMP criteria were met in subjects aged 18−60 y who received one or two vaccine doses and in subjects aged > 60 y who received two vaccine doses. At Month 12, the CHMP criteria were met only in subjects aged 18−60 y who received two vaccine doses. Persistence of HI immune response against the vaccine strain was higher in subjects without prior influenza vaccination. Exploratory analyses showed that two doses of the H1N1 2009 vaccine induced persistence of H1N1-specific CD4+ T cells up to Month 6 and memory B cells up to Month 12. In conclusion, HI immune responses persisted up to 12 mo after vaccination with one-dose and two-dose regimens of the AS03-adjuvanted 3.75 µg HA H1N1 2009 pandemic influenza vaccine, although not all three CHMP guidance criteria for both groups were met at Month 6 and Month 12. The CD4+ T cell and B cell responses also persisted up to Month 12.
- 9 April 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 9 (7) , 1512-1522
Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine
This manuscript presents data on the persistence of Hemagglutination Inhibition (HI) immune response against the A/California/7/2009 strain, six and 12 mo after adults received one dose (n = 138) or two doses (n = 102; 21 d apart) of a 3.75 µg Hemagglutinin antigen AS03-adjuvanted H1N1 2009 vaccine (NCT00968526). Two hundred forty subjects (18−60 y: 120; > 60 y: 120) were vaccinated. Immunogenicity end points were based on the European licensure criteria for pandemic influenza vaccines. Exploratory analyses assessed the cell-mediated immune response (CMI) up to Month 12 and the influence of previous influenza vaccination on persistence of immune response. At Month 6, the CHMP criteria were met in subjects aged 18−60 y who received one or two vaccine doses and in subjects aged > 60 y who received two vaccine doses. At Month 12, the CHMP criteria were met only in subjects aged 18−60 y who received two vaccine doses. Persistence of HI immune response against the vaccine strain was higher in subjects without prior influenza vaccination. Exploratory analyses showed that two doses of the H1N1 2009 vaccine induced persistence of H1N1-specific CD4+ T cells up to Month 6 and memory B cells up to Month 12. In conclusion, HI immune responses persisted up to 12 mo after vaccination with one-dose and two-dose regimens of the AS03-adjuvanted 3.75 µg HA H1N1 2009 pandemic influenza vaccine, although not all three CHMP guidance criteria for both groups were met at Month 6 and Month 12. The CD4+ T cell and B cell responses also persisted up to Month 12.